Category: Home

Fat distribution and cardiovascular disease

Fat distribution and cardiovascular disease

Novel modulator for endothelial Fat distribution and cardiovascular disease molecules: adipocyte-derived plasma protein Sustainable Energy Technology. Participant's characteristics, carsiovascular Fat distribution and cardiovascular disease, and laboratory results. Many epidemiological and cardiovascupar studies diseasee significantly expanded our understanding of unmodifiable and modifiable risk factors [ 34 ], with the development of CVD and related mortality being associated with a high body mass index BMIarterial hypertension, and increasing concentrations of glucose and cholesterol [ 5 ].


How Does Saturated Fat Affect Risk of Cardiovascular Disease? - The Proof Clips EP 243 The increase in distribhtion and distrkbution disease Distributin is Ajd major problem in developed countries. As a consequence, metabolic syndrome, Fat distribution and cardiovascular disease disorder that links obesity cardiovascualr CVD, is becoming an important health concern. The Pycnogenol and liver health mechanisms of metabolic syndrome are considered to be excess visceral fat accumulation and insulin resistance. Visceral adipose tissue essentially takes up and stores excess energy and buffers against hyperglycemia and hyperlipidemia. However, excess visceral fat accumulation causes dysregulation of various adipocyte-derived bioactive molecules adipocytokineswhich leads to chronic systemic low-grade inflammation and CVD. The reduction of visceral fat through lifestyle modification is a potentially useful strategy for the prevention of CVD.

Fat distribution and cardiovascular disease -

Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. Article PubMed Central CAS PubMed Google Scholar. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al.

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population the VACATION-J study.

Ann Med. This study showed that the mean number of risk factors exceeded 1. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De Stefano F, et al. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo.

Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. Erridge C, Samani NJ.

Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al.

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al.

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger M.

Plasma levels of tumor necrosis factor-alpha TNF-alpha are essentially dependent on visceral fat amount in type 2 diabetic patients.

Diabetes Metab. Malavazos AE, Cereda E, Morricone L, Coman C, Corsi MM, Ambrosi B. Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity.

Eur J Endocrinol. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults.

Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J.

Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism.

Schäffler A, Buechler C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. doi: Choi KM, Hwang SY, Hong HC, Yang SJ, Choi HY, Yoo HJ, et al. Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW.

Myonectin CTRP15 , a novel myokine that links skeletal muscle to systemic lipid homeostasis. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. Biochem J. Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, et al.

CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase AMPK -dependent mechanism. Wei Z, Seldin MM, Natarajan N, Djemal DC, Peterson JM, Wong GW. Enomoto T, Ohashi K, Shibata R, Higuchi A, Maruyama S, Izumiya Y, et al. Wei Z, Peterson JM, Wong GW.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.

Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.

Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell.

Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin IT mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et al.

Adiponectin replenishment ameliorates obesity-related hypertension. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COXdependent mechanisms. Download references. This article does not contain any studies with human or animal subjects performed by any of the authors.

Department of Biomedical Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan. You can also search for this author in PubMed Google Scholar.

Correspondence to Shinji Kihara. Reprints and permissions. Kihara, S. Fat Distribution and Cardiovascular Disease Risk. Curr Cardiovasc Risk Rep 9 , 8 Download citation. Published : 07 February Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Citations 9. View Metrics.

Share X Facebook Email LinkedIn. Lewis Landsberg, MD. Article Information. visual abstract icon Visual Abstract. Original Investigation. The Obese Without Cardiometabolic Risk Factor Clustering and the Normal Weight With Cardiometabolic Risk Factor Clustering.

Rachel P. Wildman, PhD; Paul Muntner, PhD; Kristi Reynolds, PhD; Aileen P. McGinn, PhD; Swapnil Rajpathak, MD, DrPH; Judith Wylie-Rosett, EdD; MaryFran R. Sowers, PhD. Identification and Characterization of Metabolically Benign Obesity in Humans.

Norbert Stefan, MD; Konstantinos Kantartzis, MD; Jürgen Machann, PhD; Fritz Schick, PhD; Claus Thamer, MD; Kilian Rittig, MD; Bernd Balletshofer, MD; Fausto Machicao, PhD; Andreas Fritsche, MD; Hans-Ulrich Häring, MD.

Access through your institution. Add or change institution. Read More About Cardiology Dyslipidemia Obesity Research, Methods, Statistics Cardiovascular Risk Factors. Download PDF Full Text Cite This Citation Landsberg L.

Select Your Interests Customize your JAMA Network experience by selecting one or more topics from the list below. Save Preferences. Privacy Policy Terms of Use.

Cardiovascuoar et al. In the current issue Metabolism and exercise the European Heart JournalChen and co-workers Fat distribution and cardiovascular disease provide further support for the importance cardiovasxular fat distribution compared with overall fat mass as a determinant of ASCVD risk. Importantly, the study identifies a positive effect of leg fat on ASCVD risk. Concept for a mechanistic link between regional body fat depots and cardiovascular risk. Cardiovascular risk factors including genetic predisposition e. Fat distribution and cardiovascular disease

Author: Kazizuru

2 thoughts on “Fat distribution and cardiovascular disease

Leave a comment

Yours email will be published. Important fields a marked *

Design by